

Definition

‘Values’ refers to the desirability or personal importance a respondent places on the benefits and risks of an option.

Sample Tool

The things that are important to me when making a decision about osteoporosis therapies

Below are listed some things women consider when making a decision about osteoporosis therapies. Please show how important these are to you by circling a number from **0** (not at all important to me) to **10** (extremely important to me).

1. How important is **protection from hip fractures** to you when making a decision about osteoporosis therapy?

0	1	2	3	4	5	6	7	8	9	10
not at all										extremely
important to me										important to me

2. How important is **protection from spinal fractures** to you when making a decision about osteoporosis therapies?

0	1	2	3	4	5	6	7	8	9	10
not at all										extremely
important to me										important to me

3. How important is **the ability to stay active** to you when making a decision about osteoporosis therapies?

0	1	2	3	4	5	6	7	8	9	10
not at all										extremely
important to me										important to me

User Manual - Values

4. What **other positive factors** are important to you when making a decision about osteoporosis therapies? (Please specify any positive factors you have considered and rate their importance to you)

a) _____	0	1	2	3	4	5	6	7	8	9	10
b) _____	0	1	2	3	4	5	6	7	8	9	10
c) _____	0	1	2	3	4	5	6	7	8	9	10
	not at all									extremely	
	important to me									important to me	

5. How important is the **risk of breast cancer** to you when making a decision about osteoporosis therapies

0	1	2	3	4	5	6	7	8	9	10
not at all									extremely	
important to me									important to me	

6. How important is the **risk of blood clots** to you when making a decision about osteoporosis therapies?

0	1	2	3	4	5	6	7	8	9	10
not at all									extremely	
important to me									important to me	

7. How important is the **risk of gastro-intestinal side effects (such as ulcer)** to you when making a decision about osteoporosis therapies?

0	1	2	3	4	5	6	7	8	9	10
not at all									extremely	
important to me									important to me	

8. What **other negative factors** are important to you when making a decision about osteoporosis therapies? (Please specify any negative factors you have considered and rate their importance to you)

a) _____	0	1	2	3	4	5	6	7	8	9	10
b) _____	0	1	2	3	4	5	6	7	8	9	10
c) _____	0	1	2	3	4	5	6	7	8	9	10
	not at all									extremely	
	important to me									important to me	

Values © AM O'Connor 2004

User Manual - Values

Directions for Use

In a short introductory statement, respondents should be asked to consider a number of factors that are viewed as important by people making a specific decision, and then asked to show how important each factor is by circling a number from 0 to 10 that best indicates the level of personal importance the respondent places on the factor, with 0 being 'not at all important to me in this decision' and 10 being 'extremely important to me in this decision'.

Respondents can also be asked to identify some personal positive and negative factors, and rate their personal importance on the 11-point scale.

Values can be measures over time, both before and after making a decision.

Psychometric Properties

Test-retest coefficients range from 0.79 to 0.91 [8].

Measures explain and discriminate between those making different decisions [1, 8].

When values are correlated with the choice, correlations between choices and values change over time [1] and differ between decision aids and comparison interventions [3], especially among those who are changing the status quo [4].

Clinical Applications Using this Tool

HRT [1-4, 8]

Lung cancer [5]

Autologous blood donation [6]

Osteoporosis [7]

Availability

You may use any of these scales at no cost without permission.

These tools are protected by copyright but are freely available for you to use, provided you cite the reference in any questionnaires or publications.

Suggested Citation

O'Connor AM. User Manual – Values [document on the Internet]. Ottawa: Ottawa Hospital Research Institute; © 2004 [cited YYYY MM DD]. 4 p. Available from http://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Values.pdf

References

1. O'Connor AM, Tugwell P, Wells GA, Elmslie T, Jolly E, Hollingworth G, McPherson R, Bunn H, Graham I, Drake E. A decision aid for women considering hormone therapy after menopause: decision support framework and evaluation. *Patient Education and Counseling* 1998; 33: 267-279.
2. O'Connor AM, Tugwell P, Wells GA, Elmslie T, Jolly E, Hollingworth G, McPherson R, Drake E, Hopman W, MacKenzie T. Randomized Trial of a Portable, Self-administered Decision Aid for Postmenopausal Women Considering Long-term Preventive Hormone Therapy. *Medical Decision Making* 1998; 18: 295-303.
3. Dodin S, Légaré F, Daudelin G, Tetroe J, O'Connor A. Prise de décision en matière d'hormonothérapie de remplacement: Essai clinique randomisé. *Canadian Family Physician/Le Médecin de famille canadien*. 47:1586-1593, 2001.
4. O'Connor, AM, Wells GA, Tugwell P, Laupacis A, Elmslie T, Drake E. The value of an 'explicit' values clarification exercise in a woman's decision aid regarding postmenopausal hormone therapy. *Health Expectations* 1999;2:21-32.
5. Fiset V, O'Connor AM, Evans W, Graham I, DeGrasse C, Logan J. Development and evaluation of a decision aid for patients with stage IV non-small cell lung cancer. *Health Expectations* 2000; 3: 125-136.
6. Grant FC, Laupacis A, O'Connor AM, Rubens F, Robblee J. Evaluation of a decision aid for patients considering autologous blood donation before open-heart surgery. *Canadian Medical Association Journal* 2001; 164: 1139-1144.
7. Cranney A, O'Connor AM, Jacobsen MJ, Tugwell P, Adachi JD, Ooi DS, Waldegger L, Goldstein R, Wells GA. Development and pilot testing of a decision aid for postmenopausal women with osteoporosis. *Patient Education and Counseling* 2002; 47: 245-255.
8. O'Connor A, Tugwell P, Wells G. (1994) Testing a portable, self-administered decision aid for post menopausal women considering long-term hormone replacement therapy to prevent osteoporosis and heart disease. *Medical Decision Making*, 14(4);438 (Abstract).